stockrowAllogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023.
- Revenue
- +20,990.9%
- EPS
- +43.5%
- Free cash flow
- +17.7%
Quarter to June 2026, against a year earlier
Follow ALLO
Alert me
Allogene Therapeutics, Inc. (ALLO) EV/Sales
As of 6 November 2026, Allogene Therapeutics, Inc. (ALLO) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from −2,449× (November 2023) to 6,278× (July 2023); the current reading is higher than 46% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 1,408× | 12.01% |
| FY2023 | 1,257× | (36.18%) |
| FY2022 | 1,969× | 14,218.30% |
| FY2021 | 13.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 74.7× | (98.17%) |
| Mar 2024 | 4,091× | 225.51% |
| Dec 2023 | 1,257× | (21.17%) |
| Sep 2023 | 1,594× | (59.07%) |
| 10 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZURA Zura Bio Limited compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| ALLO Allogene Therapeutics, Inc. | 2.0× |
| EDIT Editas Medicine, Inc. compare | 2.7× |
| CCCC C4 Therapeutics, Inc. compare | 7.4× |
| ALT Altimmune, Inc. compare | 1,970× |
| LYEL Lyell Immunopharma, Inc. compare | 12,336× |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)